Aspire Biopharma Holdings (ASBP) Net Income towards Common Stockholders (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Net Income towards Common Stockholders of -$3.2 million for Q1 2026, up 79.78% year-over-year from -$1.8 million in Q1 2025, and up 60.13% quarter-over-quarter from -$8.1 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 79.78% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$13.9 million (up 19.73% YoY), while the FY2025 annual figure was -$19.3 million, down 54.26% from the prior year.
- Net Income towards Common Stockholders advanced to -$3.2 million in Q1 2026 per ASBP's latest filing, from -$8.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.5 million in Q2 2023 and bottomed at -$15.9 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$162636.0 in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 11635.1% — and 2023, when it soared 5970.52%.
- Aspire Biopharma Holdings' Net Income towards Common Stockholders stood at -$88600.0 in 2022, then fell by 23.03% to -$109003.0 in 2023, then sank by 446.44% to -$595639.0 in 2024, then plunged by 1257.0% to -$8.1 million in 2025, then jumped by 60.13% to -$3.2 million in 2026.
- Business Quant data shows ASBP's Net Income towards Common Stockholders at -$3.2 million in Q1 2026, -$8.1 million in Q4 2025, and -$2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.27 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -8.08 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -595,639.00 |
| Sep 30, 2024 | -216,269.00 |
| Jun 30, 2024 | -602,258.00 |
| Mar 31, 2024 | -2.47 Mn |
| Dec 31, 2023 | -109,003.00 |
| Sep 30, 2023 | -69,258.00 |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 574,487.00 |
| Dec 31, 2022 | -88,600.00 |
| Sep 30, 2022 | 861,773.00 |
| Jun 30, 2022 | 24,139.00 |
| Mar 31, 2022 | -42,007.00 |
| Dec 31, 2021 | -755.00 |
| Sep 30, 2021 | -15,310.00 |
| Mar 31, 2021 | -7,727.00 |